Urovant Sciences (UROV) Misses Q3 EPS by 38c

Urovant Sciences (NASDAQ: UROV) reported Q3 EPS of ($1.36), $0.38 worse than the analyst estimate of ($0.98).

Recent Business Highlights

• Submitted a New Drug Application for vibegron for the treatment of patients with overactive bladder to the U.S. Food and Drug Administration (FDA) in December 2019.
• Initiated a Phase 2a study of URO-902, a novel gene therapy product for patients with overactive bladder that have failed oral pharmacologic therapy.
• Entered into a $300 million low interest, interest-only, five-year term loan facility with Sumitomo Dainippon Pharma.

“This has been an exciting and transformational quarter for our company, marked by key milestones across all aspects of our business,” said Keith A. Katkin, chief executive officer of Urovant Sciences. “We submitted our New Drug Application for vibegron for the treatment of patients with overactive bladder to the FDA ahead of schedule, initiated a Phase 2a study of our novel gene therapy product, URO-902 and entered into a transformative relationship with Sumitomo Dainippon Pharma. We now look forward to our interactions with the FDA as we prepare to bring to market a potentially best in class therapeutic option for the treatment of patients suffering from overactive bladder.”

For earnings history and earnings-related data on Urovant Sciences (UROV) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• zSpace, Inc. (ZSPC) Reports Q2 results
• Boqii says no new developments behind unusual trading activity